RNA METHYLATION IN NORMAL AND MALIGNANT BLOOD DEVELOPMENT

Grant number: 1182804 | Funding period: 2020 - 2022

Completed

Abstract

Sequencing studies that have compared the genomes and epigenomes of normal and malignant cells have revolutionised our understanding of cancer and have led to the development of new therapeutic strategies. Herein, we propose to study how the RNA modification m6A is regulated during physiological blood development and dysregulated in leukaemia.

Related publications (2)

Non-genetic heterogeneity, altered cell fate and differentiation therapy

Alexander C Lewis, Lev M Kats

2021-02-08

Altered capacity for self-renewal and differentiation is a hallmark of cancer, and many tumors are composed of cells with a develo..

A saturating mutagenesis CRISPR-Cas9-mediated functional genomic screen identifies cis- and trans-regulatory elements of Oct4 in murine ESCs

Matthew C Canver, Pratibha Tripathi, Michael J Bullen, Moshe Olshansky, Yogesh Kumar, Lee H Wong, Stephen J Turner, Samuel Lessard, Luca Pinello, Stuart H Orkin, Partha Pratim Das

2020-11-20

Regulatory elements (REs) consist of enhancers and promoters that occupy a significant portion of the noncoding genome and control..

University of Melbourne Researchers

Lev Kats The Sir Peter Maccallum Department of Oncology

Partha Das Psychiatry